Compare Citius Pharmaceuticals Inc (CTXR) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Wix.Com Ltd — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Wix.Com Ltd trades at $74.53 (market cap $3.11B). The key difference: Wix.Com Ltd is far larger — about 228.3× Citius Pharmaceuticals Inc's market cap, and Wix.Com Ltd is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Wix.Com Ltd for 62 Days on average.
| CTXR | WIX | |
|---|---|---|
Market Cap | $13.62M | $3.11B |
Volume | 132,438 | 809,286 |
Sector | Health | Technology |
52-Week High | $1.82 | $145.54 |
52-Week Low | $0.48 | $40.43 |
Typical Hold Time | 16 Days | 62 Days |
Enterprise Value | $3.79M | $4.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Wix.com (WIX) trades at $72.97, down 1.27% on the day, with a bearish technical signal from moving averages. The company shows strong revenue growth reaching $1.99B in 2025, though net income margin remains negative at -8.19%. Recent earnings show mixed results with Q2 2026 beating expectations but Q1 2026 missing. Multiple class action lawsuits filed in September 2026 create significant legal overhang.
While analyst consensus remains bullish with 63% buy ratings and $77 price target, the combination of negative cash flow trends, legal challenges, and high valuation multiples (P/E 62.84) presents substantial risk. The stock faces headwinds from operational execution challenges despite solid revenue growth fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
